• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alimera Sciences Inc. (Amendment)

    2/13/24 3:27:46 PM ET
    $ALIM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALIM alert in real time by email
    SC 13G/A 1 altium-sc13ga.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Alimera Sciences, Inc

     

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

     

    (Title of Class of Securities)

     

    016259202

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    Page 2 of 9

     

    CUSIP No. 016259202  

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,660,000 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,660,000 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,660,000 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.0%(1)

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
                     

     

     

    (1)Based on 52,416,841 shares of Common Stock outstanding as set forth in the Issuer’s Form 10-Q dated October 27, 2023, filed with the Securities and Exchange Commission on November 2, 2023.

     

     

     

     

    Page 3 of 9

     

    CUSIP No. 016259202    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,660,000 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,660,000 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,660,000 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.0%(1)

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

     

    (1)Based on 52,416,841 shares of Common Stock outstanding as set forth in the Issuer’s Form 10-Q dated October 27, 2023, filed with the Securities and Exchange Commission on November 2, 2023.

     

     

     

     

    Page 4 of 9

     

    CUSIP No. 016259202    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    2,660,000 shares of Common Stock

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    2,660,000 shares of Common Stock

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,660,000 shares of Common Stock

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.0%(1)

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

     

    (1)Based on 52,416,841 shares of Common Stock outstanding as set forth in the Issuer’s Form 10-Q dated October 27, 2023, filed with the Securities and Exchange Commission on November 2, 2023.

     

     

     

     

    Page 5 of 9

     

    CUSIP No.  016259202    

     

    Item 1(a).   Name of Issuer:                                                         Alimera Sciences, Inc. (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices: 6310 Town Square, Suite 400

        Alpharetta, Georgia 30005

         
    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57th Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.01 per share (“Common Stock”)
         
    Item 2(e).   CUSIP Number: 016259202
           
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

    Page 6 of 9

     

    CUSIP No.  016259202    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person listed above and is incorporated by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 52,416,841 shares of Common Stock outstanding as set forth in the Issuer’s Form 10-Q dated October 27, 2023, filed with the Securities and Exchange Commission on November 2, 2023.

           

     

     

     

    Page 7 of 9

     

    CUSIP No .  016259202

      

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 13, 2024
       
    Altium Capital Management, LP

     

    By:/s/ Jacob Gottlieb
    Name:Jacob Gottlieb
    Title:CEO

     

    Altium Growth Fund, LP

     

    By:Altium Growth GP, LLC
    Its:General Partner

     

      Signature: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member of Altium Growth GP, LLC
         
      Altium Growth GP, LLC
     
      By: /s/ Jacob Gottlieb
      Name: Jacob Gottlieb
      Title: Managing Member

     

     

     

     

    Page 8 of 9

     

    EXHIBIT INDEX

     

    EXHIBIT 1:         Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

     

     

    Get the next $ALIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALIM

    DatePrice TargetRatingAnalyst
    6/25/2024Buy → Neutral
    H.C. Wainwright
    3/25/2024$10.00Buy
    Maxim Group
    10/30/2023$8.00Neutral → Buy
    Alliance Global Partners
    2/25/2022$12.00 → $10.00Buy
    HC Wainwright & Co.
    8/16/2021$16.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ALIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

      Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin

      9/16/24 8:53:27 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

      PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr

      9/16/24 6:50:00 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

      PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic

      9/11/24 6:50:00 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alimera Sciences Inc.

      15-12G - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/26/24 4:55:34 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alimera Sciences Inc.

      EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/23/24 12:15:05 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alimera Sciences Inc.

      EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)

      9/23/24 12:15:02 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alimera Sciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Alimera Sciences from Buy to Neutral

      6/25/24 7:18:10 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Alimera Sciences with a new price target

      Maxim Group initiated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00

      3/25/24 7:50:48 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded Alimera Sciences from Neutral to Buy and set a new price target of $8.00

      10/30/23 11:06:19 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Financials

    Live finance-specific insights

    See more
    • Alimera Sciences Reports Second Quarter 2024 Results

      Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea

      8/6/24 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

      Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a

      6/24/24 6:50:44 AM ET
      $ALIM
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences Reports First Quarter 2024 Results

      Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup

      5/14/24 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Leadership Updates

    Live Leadership Updates

    See more
    • Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

      12/12/23 7:30:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Appoints Maggie A. Pax to Its Board of Directors

      ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

      11/8/23 4:30:00 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alimera Sciences Appoints Jason Werner as Chief Operating Officer

      ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we

      10/3/23 8:00:00 AM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/18/24 4:30:11 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      9/16/24 5:10:24 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alimera Sciences Inc.

      SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)

      6/24/24 7:30:16 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Maltz Elliot

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:54:11 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kaseta Michael

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:53:50 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Marketing Officer & SVP Holland David returned 187,756 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ALIMERA SCIENCES INC (0001267602) (Issuer)

      9/18/24 9:53:32 PM ET
      $ALIM
      Biotechnology: Pharmaceutical Preparations
      Health Care